Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up0.18% Nasdaq Up0.26%

Threshold Pharmaceuticals Inc. (THLD)

-NasdaqCM
3.88 Up 0.05(1.31%) 9:41AM EDT - Nasdaq Real Time Price
Get the big picture on all your investments.
ProfileGet Profile for:
Threshold Pharmaceuticals Inc.
170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States - Map
Phone: 650-474-8200
Fax: 650-474-2529
Website: http://www.thresholdpharm.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:53

Business Summary 

Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule, TH-302, is being evaluated in two pivotal Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; and various earlier-stage clinical trials for therapeutic areas, including advanced leukemias, multiple myeloma, advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Threshold Pharmaceuticals, Inc. has a license and co-development agreement with Merck KGaA to co-develop and commercialize TH-302; and license agreement with Eleison Pharmaceuticals, Inc. for the development and commercialization of glufosfamide for the treatment of cancer in humans and animals. The company was founded in 2001 and is headquartered in South San Francisco, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Threshold Pharmaceuticals Inc.

Corporate Governance 
Threshold Pharmaceuticals Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 10; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Harold E. Selick Ph.D., 60
Exec. Chairman and Chief Exec. Officer
849.00K0.00
Mr. Joel A. Fernandes , 44
Principal Financial Officer, Principal Accounting Officer, VP of Fin. and Controller
339.00K0.00
Dr. Tillman E. Pearce M.D., 57
Chief Medical Officer
483.00K39.00K
Mr. Robert L. Simon , 69
Sr. VP of Regulatory Affairs & Quality Assurance
406.00K0.00
Dr. Nipun Davar Ph.D., MBA,
VP of Pharmaceutical Devel. and Manufacturing
356.00K20.00K
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders